Clinical-Stage Partnering and Royalty Rate Trends in Biopharma: New Reports Analyze Over 3,400 Deals from 2015–2026
Key Insights
Two new industry reports from ResearchAndMarkets.com provide comprehensive analysis of over 1,859 clinical-stage partnering agreements and 1,567 royalty-disclosing licensing transactions in the pharmaceutical and biotechnology sectors.
The clinical-stage report covers deal structures, upfront payments, milestone triggers, and royalty rates across Phase I, II, and III agreements, with contract documents where available.
The royalty rates report examines financial terms across 1,567 licensing transactions since 2015, offering benchmarking data on royalty clauses, license fees, and payment structures.
Two major industry reports released on July 17, 2026, by ResearchAndMarkets.com offer an unprecedented window into the financial and strategic architecture of biopharmaceutical dealmaking, collectively analyzing more than 3,400 licensing and partnering transactions spanning 2015 to 2026.
The first report, "Clinical Stage Partnering Terms and Agreements in Pharmaceuticals and Biotechnology 2020–2026," catalogs over 1,859 clinical-stage deals announced since 2020, including financial terms where publicly available. The second, "Royalty Rates in Pharmaceutical and Biotechnology Deals 2015–2026," examines 1,567 licensing transactions with disclosed royalty rates, providing granular detail on payment structures, license fees, and milestone terms.
Clinical-Stage Partnering: Structures and Strategies
At the clinical stage, licensing agreements typically grant the licensee exclusive rights or options to develop a licensor's product or technology, often covering Phase I, Phase II, and Phase III trials. These agreements are frequently multi-component, involving collaborative R&D, co-development, and commercialization strategies.
The clinical-stage report provides detailed intelligence on deal activity by year, development stage, therapeutic area, technology type, and key dealmakers. It analyzes headline values, upfront payments, milestone triggers, and royalty rates for Phase I, Phase II, and Phase III agreements. The report also reviews leading deals by value and profiles the 25 most active dealmakers.
"While headline financial terms provide a broad overview, contract documents reveal the actual triggers and conditions for these payments — details often missing from press releases and traditional deal databases," the report notes, emphasizing the value of analyzing actual contract agreements submitted to the SEC.
Each deal record is indexed by company, headline value, stage of development at signing, deal type, and specific therapy focus. The report addresses critical questions including what specific rights are granted, how exclusivity terms apply, who controls development and commercialization, and how intellectual property rights are handled.
Royalty Rates: A Decade of Licensing Data
The royalty rates report serves as a definitive guide to royalty-based agreements in the pharmaceutical, biotechnology, and diagnostics sectors. It explores how payments are structured, triggered, and negotiated — insights the report describes as "often unavailable in press releases or databases."
For smaller companies and dealmakers, the report sheds light on the intricacies of payment clauses and provides guidance on navigating negotiations with potential partners. It includes analysis of royalty rate trends since 2015, case studies of licensing deals with disclosed royalty rates, and comprehensive listings organized by company, therapeutic area, and technology type.
The report addresses key questions such as agreed royalty rates and terms, how rights and exclusivity are negotiated, terms for development and commercialization, and how audits, confidentiality, and disputes are managed.
Industry Leaders and Active Dealmakers
Both reports feature extensive profiles of leading biopharmaceutical companies. Among the companies featured across the two reports are AbbVie (search), Amgen, AstraZeneca, Gilead Sciences, Moderna, Novo Nordisk, Regeneron Pharmaceuticals, Sanofi, Takeda Pharmaceutical (search), Alnylam Pharmaceuticals, Beam Therapeutics, BioNTech, CRISPR Therapeutics, Dragonfly Therapeutics, Innovent Biologics, Ionis Pharmaceuticals, Jazz Pharmaceuticals, Legend Biotech, and Vertex Pharmaceuticals, among many others.
The reports are positioned as essential resources for C-level executives, business development professionals, licensing managers, legal advisors, and financial professionals involved in biopharma dealmaking, providing tools to benchmark deal structures, optimize negotiation strategies, and conduct data-backed due diligence.